Boston Immune Technologies & Therapeutics
http://www.bostonimmunetech.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boston Immune Technologies & Therapeutics
BioInvent Using New Screening Platforms To Identify Novel IO Targets
Swedish biotech BioInvent uses its extensive antibody library to identify new immuno-oncology targets and translate these into therapies. Following the delivery of some impressive early-stage research at the annual Society for Immunotherapy for Cancer conference, CEO Martin Welschof caught up with In Vivo to share more about the firm’s story so far.
Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Asia Deal Watch: Emmaus, Kainos Pursue R&D In Cancers With Limited Therapy Options
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice